Principal Investigator
Matthew Schlumbrecht
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20240297
Clinical Trial Summary
A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects with Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancers
Phase
Phase II/III
Funding Agency/Sponsor
Industrial
Disease
Gynecologic Cancer
Contact Information
Phone Number
305-243-2647